Up Close with Glofitamab
Last Updated: May 16, 2025
Discover more about glofitamab-gxbm (COLUMVI™).
Related Resources:
PQI
PQI: Glofitamab-gxbm (COLUMVI®) for the Treatment of Relapsed or Refractory Large B-cell Lymphoma
Last Updated: 01/12/2024
Perspectives
OncolyticsToday: The Bispecific Antibody Revolution
Author: KELLY BRUNK
Last Updated: 04/01/2024
Find Similar Resources:
Immunotherapy
Immunotherapy
Immunotherapy
Immunotherapy
Up Close with Linvoseltamab
Last Updated: 06/29/2026
Overview of BTCEs: Comparison of Bispecific T-Cell Engagers (BTCEs)
Last Updated: 04/23/2026
Example SOPs and Documents: Transitioning Patients on Bispecific T-Cell Engagers Between Care Settings
Last Updated: 07/01/2025
Example SOPs and Documents: Bispecific T-cell Engager Billing Procedure
Last Updated: 07/01/2025
Patient Education Sheet
Patient Education Sheet
Patient Education Sheet
Patient Education Sheet
Immune Globulin
Last Updated: 08/18/2026
Docetaxel and Gemcitabine
Last Updated: 08/18/2026
Durvalumab and Bacillus Calmette-Guérin
Last Updated: 08/18/2026
Mitomycin Given into the Bladder
Last Updated: 08/18/2026